US Bancorp DE Sells 858 Shares of Regeneron Pharmaceuticals, Inc. $REGN

Key Points

• US Bancorp DE reduced its stake in Regeneron Pharmaceuticals by 13.5%, now holding 5,487 shares worth approximately $2.88 million.
• Regeneron reported $12.89 EPS for the last quarter, exceeding analysts' expectations, with revenue reaching $3.68 billion, up 3.6% year-over-year.
• The company announced a quarterly dividend of $0.88 per share, reflecting an annualized yield of 0.6% and a dividend payout ratio of 8.87%.

US Bancorp DE lessened its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 13.5% in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 5,487 shares of the biopharmaceutical company's stock after selling 858 shares during the quarter. US Bancorp DE's holdings in Regeneron Pharmaceuticals were worth $2,881,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Marietta Wealth Management LLC boosted its holdings in shares of Regeneron Pharmaceuticals by 30.2% in the first quarter. Marietta Wealth Management LLC now owns 10,778 shares of the biopharmaceutical company's stock valued at $6,836,000 after buying an additional 2,501 shares during the period. Sepio Capital LP boosted its holdings in shares of Regeneron Pharmaceuticals by 33.1% in the first quarter. Sepio Capital LP now owns 3,389 shares of the biopharmaceutical company's stock valued at $2,150,000 after buying an additional 842 shares during the period. Founders Capital Management LLC boosted its holdings in shares of Regeneron Pharmaceuticals by 7.0% in the second quarter. Founders Capital Management LLC now owns 8,274 shares of the biopharmaceutical company's stock valued at $4,344,000 after buying an additional 538 shares during the period. PGGM Investments boosted its holdings in shares of Regeneron Pharmaceuticals by 159.7% in the second quarter. PGGM Investments now owns 84,397 shares of the biopharmaceutical company's stock valued at $44,308,000 after buying an additional 51,900 shares during the period. Finally, China Universal Asset Management Co. Ltd. boosted its holdings in shares of Regeneron Pharmaceuticals by 3.9% in the first quarter. China Universal Asset Management Co. Ltd. now owns 25,629 shares of the biopharmaceutical company's stock valued at $16,255,000 after buying an additional 955 shares during the period. Institutional investors and hedge funds own 83.31% of the company's stock.

Regeneron Pharmaceuticals Trading Up 2.7%

Regeneron Pharmaceuticals stock opened at $572.60 on Wednesday. Regeneron Pharmaceuticals, Inc. has a 52 week low of $476.49 and a 52 week high of $1,024.36. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.72 and a current ratio of 4.60. The stock has a market capitalization of $60.69 billion, a P/E ratio of 14.43, a PEG ratio of 1.78 and a beta of 0.31. The stock has a 50-day simple moving average of $573.72 and a 200 day simple moving average of $563.52.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its quarterly earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 EPS for the quarter, topping analysts' consensus estimates of $8.43 by $4.46. Regeneron Pharmaceuticals had a return on equity of 15.06% and a net margin of 31.37%.The business had revenue of $3.68 billion during the quarter, compared to analysts' expectations of $3.30 billion. During the same quarter last year, the company posted $11.56 earnings per share. Regeneron Pharmaceuticals's quarterly revenue was up 3.6% on a year-over-year basis. Analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Wednesday, September 3rd. Stockholders of record on Monday, August 18th were paid a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date was Monday, August 18th. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is currently 8.87%.

Analyst Upgrades and Downgrades

REGN has been the subject of several research analyst reports. Jefferies Financial Group upped their price target on shares of Regeneron Pharmaceuticals from $813.00 to $831.00 and gave the company a "buy" rating in a report on Wednesday, August 27th. Guggenheim increased their target price on shares of Regeneron Pharmaceuticals from $810.00 to $815.00 and gave the stock a "buy" rating in a report on Friday, August 1st. Truist Financial reduced their target price on shares of Regeneron Pharmaceuticals from $940.00 to $812.00 and set a "buy" rating for the company in a report on Monday, August 11th. Raymond James Financial upgraded shares of Regeneron Pharmaceuticals to a "moderate buy" rating in a report on Tuesday, September 2nd. Finally, Sanford C. Bernstein increased their target price on shares of Regeneron Pharmaceuticals from $753.00 to $781.00 and gave the stock an "outperform" rating in a report on Wednesday, August 27th. Three analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating, seven have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $817.88.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.